A wave of novel therapeutic modalities is opening up new possibilities for diseases long considered untreatable, according to a report from Genetic Engineering & Biotechnology News. The piece highlights macrocycles, de novo antibodies, and mRNA therapies as key technologies now being deployed against the so-called 'undruggable' targets that have frustrated conventional small-molecule drug development.
The article notes that these approaches are gaining traction in both academic labs and biotech pipelines. Macrocycles, for instance, offer a middle ground between small molecules and biologics, capable of binding flat protein surfaces that traditional drugs cannot reach. Similarly, computationally designed de novo antibodies and platform-based mRNA therapeutics are enabling rapid targeting of previously inaccessible intracellular and extracellular proteins.
Broadly, the report frames these modalities as an expansion of the drug discovery toolbox rather than a direct replacement for existing methods. While specific clinical data or regulatory milestones are not cited, the piece emphasizes the growing shift in industry R&D investment toward these frontier technologies to address unmet patient needs. The underlying message is one of cautious optimism: the 'undruggable' label is gradually being challenged by scientific ingenuity, though hurdles in delivery, immunogenicity, and manufacturing remain.
For companies pursuing these strategies, the investment case hinges on platform validation and proof-of-concept in humans. No stock movements or financial figures are mentioned in the source.
Patient access remains an open question, as novel modalities often carry higher development costs and complex manufacturing requirements that could affect pricing and availability if approved.